Research programme: reduced gastric irritation NSAIDs - Oxford Pharmascience

Drug Profile

Research programme: reduced gastric irritation NSAIDs - Oxford Pharmascience

Alternative Names: OXP 006; OXP 007; OXPzero™ Aspirin

Latest Information Update: 17 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Oxford Pharmascience
  • Class Nonsteroidal anti-inflammatories; Phenylacetates; Salicylic acids; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Musculoskeletal pain
  • Discontinued Cardiovascular disorders

Most Recent Events

  • 09 Nov 2016 Discontinued for OXPzero™ aspirin programme for Cardiovascular disorders in United Kingdom (PO)
  • 02 Jul 2015 Early research in Cardiovascular disorders in United Kingdom (PO) prior to July 2015
  • 03 Feb 2015 Oxford Pharmascience plans a phase I trial in healthy volunteers in the UK (NCT02351024)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top